Gyre Therapeutics, Inc. (GYRE) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 8.99%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | 8.99% | Share-based compensation / revenue. Period ending 2026-06-30. $9.87M ÷ $109.82M × 100 ≈ 8.99% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | (m) | Research and Development Expense |
| Revenue | 109.82M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 9.87M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -22.15M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $109.82M | $9.87M | $-22.15M | (m) | (m) | 8.99% | (m) | (m) |
| 2026-03-31 | $17.34M | $117.05M | $9.23M | $-141.00K | (m) | 14.82% | 7.89% | (m) | (m) |
| 2025-12-31 | $13.70M | $116.59M | $7.16M | $11.49M | (m) | 11.75% | 6.14% | (m) | (m) |
| 2025-09-30 | $12.60M | $107.27M | $3.13M | $12.03M | (m) | 11.74% | 2.92% | (m) | (m) |
| 2025-06-30 | $13.01M | $102.19M | $2.22M | $9.34M | (m) | 12.73% | 2.17% | (m) | (m) |
| 2025-03-31 | $12.94M | $100.64M | $1.33M | $10.37M | (m) | 12.85% | 1.32% | (m) | (m) |
| 2024-12-31 | $12.02M | $105.76M | $831.00K | $16.16M | (m) | 11.37% | 0.79% | (m) | (m) |
| 2024-09-30 | (m) | $105.03M | $7.15M | $-76.07M | (m) | (m) | 6.81% | (m) | (m) |
| 2024-06-30 | (m) | $111.59M | $7.01M | $-67.53M | (m) | (m) | 6.28% | (m) | (m) |
| 2024-03-31 | (m) | $115.69M | $7.08M | $-65.82M | (m) | (m) | 6.12% | (m) | (m) |
| 2023-12-31 | (m) | $113.45M | $7.28M | $-67.23M | (m) | (m) | 6.42% | (m) | (m) |
| 2023-09-30 | (m) | (m) | $654.00K | $-44.26M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | (m) | $780.00K | $-47.80M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | (m) | $1.04M | $6.27M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | (m) | $1.34M | $-8.61M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $28.51M | (m) | $1.77M | $11.35M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $48.06M | (m) | $2.26M | $-8.71M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $61.58M | $6.67M | $2.89M | $-80.16M | (m) | 923.92% | 43.42% | (m) | (m) |
| 2021-12-31 | $68.89M | $7.34M | $3.40M | $-87.89M | (m) | 938.80% | 46.40% | (m) | (m) |
| 2021-09-30 | $67.31M | $6.93M | $3.64M | $-86.42M | (m) | 971.42% | 52.56% | (m) | (m) |
| 2021-06-30 | $59.21M | $5.52M | $4.00M | $-77.29M | (m) | 1072.01% | 72.37% | (m) | (m) |
| 2021-03-31 | $56.72M | $6.05M | $3.85M | $-74.74M | (m) | 937.74% | 63.61% | (m) | (m) |
| 2020-12-31 | $52.98M | $20.95M | $3.63M | $-57.37M | (m) | 252.89% | 17.31% | (m) | (m) |
| 2020-09-30 | $49.21M | (m) | $3.38M | $-52.52M | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | $46.89M | (m) | $3.11M | $-49.61M | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | $45.10M | (m) | $3.18M | $-46.63M | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $43.86M | (m) | $3.20M | $-57.28M | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | $41.30M | (m) | $3.27M | $-54.97M | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | $36.95M | (m) | $3.18M | $-50.12M | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | $29.73M | (m) | $2.83M | $-42.86M | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $21.47M | $6.00K | $2.61M | $-33.82M | (m) | 357900.00% | 43433.33% | (m) | (m) |
| 2018-09-30 | $16.80M | (m) | $2.17M | $-27.97M | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | $15.03M | (m) | $1.79M | $-25.50M | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | $14.56M | (m) | $1.35M | $-24.33M | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $12.85M | (m) | $863.00K | $-21.82M | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | $12.40M | (m) | $686.00K | $-21.21M | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | $11.99M | (m) | $548.00K | $-21.05M | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | $11.33M | (m) | $602.00K | $-20.02M | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $11.55M | (m) | $635.00K | $-20.42M | (m) | (m) | (m) | (m) | (m) |
| 2016-09-30 | $10.21M | (m) | $696.00K | $-19.88M | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | $8.30M | (m) | $561.00K | $-18.05M | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | $6.86M | (m) | $435.00K | $-15.34M | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | $5.96M | (m) | $326.00K | $-13.80M | $1.48M | (m) | (m) | -9.34× | Reported |
| 2015-09-30 | $5.59M | (m) | $190.41K | $-10.92M | $1.48M | (m) | (m) | -7.37× | Reported |
| 2015-06-30 | $7.99M | $212.00K | $3.23M | $-20.94M | (m) | 3770.28% | 1522.64% | (m) | (m) |
| 2015-03-31 | $12.76M | $248.00K | $3.52M | $-24.78M | (m) | 5144.76% | 1418.15% | (m) | (m) |
| 2014-12-31 | $19.50M | $275.00K | $3.47M | $-29.71M | $23.00K | 7090.55% | 1262.55% | -1291.91× | Reported |
| 2014-09-30 | $27.90M | $241.00K | $3.68M | $-38.29M | $30.00K | 11575.52% | 1525.31% | -1276.37× | Reported |
| 2014-06-30 | $35.55M | $216.00K | $4.16M | $-46.45M | $38.00K | 16460.19% | 1925.93% | -1222.34× | Reported |
| 2014-03-31 | $39.60M | $180.00K | $4.43M | $-50.70M | $46.00K | 22000.00% | 2459.44% | -1102.13× | Reported |
| 2013-12-31 | $38.84M | $3.63M | $5.22M | $-47.22M | $53.00K | 1070.27% | 143.73% | -890.87× | Reported |
| 2013-09-30 | $40.43M | $4.13M | $5.54M | $-50.17M | $61.00K | 979.79% | 134.15% | -822.43× | Reported |
| 2013-06-30 | $36.55M | $4.89M | $5.68M | $-45.12M | $68.00K | 746.79% | 116.14% | -663.53× | Reported |
| 2013-03-31 | $39.61M | $38.54M | $7.54M | $-18.40M | $76.00K | 102.77% | 19.57% | -242.08× | Reported |
| 2012-12-31 | $49.09M | $57.86M | $7.85M | $-8.14M | $86.00K | 84.84% | 13.56% | -94.63× | Reported |
| 2012-09-30 | $62.82M | $76.22M | $8.47M | $-2.02M | $101.00K | 82.42% | 11.11% | -20.03× | Reported |
| 2012-06-30 | $81.83M | $94.40M | $9.18M | $-3.26M | $120.00K | 86.68% | 9.72% | -27.13× | Reported |
| 2012-03-31 | $89.50M | $81.50M | $8.27M | $-20.06M | $127.00K | 109.81% | 10.14% | -157.96× | Reported |
| 2011-12-31 | $95.22M | $97.64M | $8.51M | $-9.74M | $132.00K | 97.52% | 8.72% | -73.83× | Reported |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | $64.55M | $85.71M | $4.94M | $13.12M | $153.00K | 75.30% | 5.76% | 85.72× | Reported |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | $40.18M | $25.06M | $2.45M | $-40.33M | $217.00K | 160.32% | 9.79% | -185.83× | Reported |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |